Ascendia

  MARKET NEWS

Thermo Fisher Scientific Introduces Sequential Protein/DNA/RNA Extraction Kit That Enables Genomic, Transcriptomic & Proteomic Analysis from a Single Sample to Support Cancer & Disease Research
Cellares & University of Wisconsin School of Medicine & Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors 
Affibody’s Licensee Announces Positive Data for Phase 1 Study Demonstrating Complete & Sustained Inhibition of Terminal Complement
Axplora Announces Multi-Million Investment to Expand Lyophilization at Le Mans & Appoints New Head of Site  
Korsana Biosciences Emerges From Stealth With $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases
Axol Bioscience Acquires Ophthalmology Business From Newcells Biotech
Evogene & Queensland University of Technology Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics & $200 Million Concurrent Private Placement
Nuclera & leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
Deciphera Pharmaceuticals Announces US FDA Acceptance for Filing of NDA for Tirabrutinib in Patients With Relapsed or Refractory PCNSL

  EXPERT CONTENT & RESOURCES

Jinying Ning, PhD

Drug Combination Screening in Oncology: Advancing Predictive Strategies for Precision Drug Development

Jinying Ning, PhD, reports combination therapy is no longer an optional strategy in oncology drug development. The biological complexity of cancer demands approaches that account for pathway redundancy, adaptive resistance, and tumor heterogeneity.

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

Low bioavailability due to poor API solubility is one of the major challenges to be overcome when developing oral dosage form drug products. An effective way of addressing this problem is to transform low solubility APIs into amorphous solid dispersions (ASDs) and can often be achieved via hot melt extrusion (HME).

Single B Cell Antibody Discovery: Improving Therapeutic Candidate Selection in Drug Development

Single B Cell Antibody Discovery: Improving Therapeutic Candidate Selection in Drug Development

Changchun Zha says as therapeutic pipelines become more complex, technologies that combine biological relevance with molecular accuracy are shifting from helpful additions to essential capabilities. Single B cell antibody discovery supports this transition by capturing naturally occurring antibodies, preserving native chain pairing, and producing sequence-defined candidates from the beginning.

  FEATURED EDITORIAL

  COMPANY PROFILE

Bora Pharmaceuticals is a global contract development and manufacturing organization (CDMO) specializing in complex oral solid dosage (tablets & capsules), biologics, liquids (solutions, suspensions, ophthalmics & nasal sprays), powders, semi-solids (creams, ointments & gels), and sterile injectables for pharmaceutical products for Clinical through Commercial manufacturing and packaging. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

Abstract

Intradermal delivery has long been a critical method in medical and pharmaceutical fields, offering unique advantages for diagnosis, vaccination and therapeutic applications. This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as …

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

 

The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …

WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine

WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine

By: Dr. Jens Morgenthaler, General Manager and Dr. Matthias Rischer, Head of Innovation, Losan Pharma GmbH

 Introduction

The successful formulation of small molecules is still one of the important challenges of today, especially if these drugs belong to the BioClassificationSystem …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 25 – ODT/Fast Dissolve
March 4 – Drug Delivery